Ranolazine: clinical applications and therapeutic basis.
Publication/Presentation Date
2-1-2013
Abstract
Ranolazine is currently approved for use in chronic angina. The basis for this use is likely related to inhibition of late sodium channels with resultant beneficial downstream effects. Randomized clinical trials have demonstrated an improvement in exercise capacity and reduction in angina episodes with ranolazine. This therapeutic benefit occurs without the hemodynamic effects seen with the conventional antianginal agents. The inhibition of late sodium channels as well as other ion currents has a central role in the potential use of ranolazine in ischemic heart disease, arrhythmias, and heart failure. Despite its QTc-prolonging action, albeit minimal, clinical data have not shown a predisposition to torsades de pointes, and the medication has shown a reasonable safety profile even in those with structural heart disease. In this article we present the experimental and clinical data that support its current therapeutic role, and provide insight into potential future clinical applications.
Volume
13
Issue
1
First Page
5
Last Page
16
ISSN
1179-187X
Published In/Presented At
Hawwa, N., & Menon, V. (2013). Ranolazine: clinical applications and therapeutic basis. American journal of cardiovascular drugs : drugs, devices, and other interventions, 13(1), 5–16. https://doi.org/10.1007/s40256-012-0003-2
Disciplines
Medicine and Health Sciences
PubMedID
23335347
Department(s)
Department of Medicine, Cardiology Division
Document Type
Article